Skip to main content

CSL Behring News

2020

CSL Behring News

2020

CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B

18 Jul 2024

The positive decision from the Canadian Agency for Drugs and Technologies in Health (CADTH) recognizes the importance of this one-time, single dose innovative treatment for adults with hemophilia B who require routine prophylaxis

Health Canada Authorizes CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B

26 Oct 2023

CSL’s HEMGENIX® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis

Ottawa, ON

HAEGARDA® is now available in all of Canada for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients

06 Apr 2021

HAEGARDA® is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.

COVID-19 Update

16 Feb 2021

CSL continues to provide medicines to patients around the world.

CSL Named as One of the World’s Best Employers

29 Oct 2020

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

26 May 2020

“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies

CSL Behring and SAB Therapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

08 Apr 2020

King of Prussia, Pa. and Sioux Falls, S.D., April 8, 2020

COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology,
on-track for clinical evaluation as early as summer

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

06 Apr 2020

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

Our Offer To Help Battle Coronavirus

18 Mar 2020

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.

HAEGARDA® is now available in the province of Québec for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients

05 Feb 2020

HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.

Now approved by Health Canada: Hizentra®

10 Oct 2018

Now approved by Health Canada: Hizentra® (Subcutaneous Immunoglobulin [Human] 20% Liquid) for the Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for maintenance therapy

Lifesaving Medicines Donated For Patients In The Developing World

12 Apr 2018

Ottawa – CSL Behring has shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A to the WFH Global Alliance for Progress (GAP)Program in recognition of World Hemophilia Day.